financetom
Business
financetom
/
Business
/
Equinix Seen Benefiting From Rising AI Inference Demand, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Equinix Seen Benefiting From Rising AI Inference Demand, Morgan Stanley Says
Apr 13, 2026 8:23 AM

11:00 AM EDT, 04/13/2026 (MT Newswires) -- Equinix ( EQIX ) is likely to benefit from sustained demand for colocation data center capacity, driven by an inflection in enterprise compute workloads toward AI inference, Morgan Stanley said in a Monday research report.

Morgan Stanley said its capex yield framework indicates potential revenue growth for data center real estate investment trusts as capacity expands.

The brokerage raised its 2026 and 2027 revenue growth estimates for Equinix ( EQIX ) by about 50 basis points and 130 basis points, respectively.

The company's stabilized yield is likely to improve as more capacity becomes available for leasing at attractive rates, while demand for AI inference could receive further support from the emergence of new use cases, according to the note.

Morgan Stanley said factors such as data generation from digitization at scale, the transition to hybrid IT architectures, cloud adoption, and cybersecurity are driving growth for data center REITs.

The brokerage reiterated its overweight rating on Equinix ( EQIX ) and raised its price target to $1,250 per share from $1,075.

Price: 1044.78, Change: +14.54, Percent Change: +1.41

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biodexa Pharmaceuticals Gets Exclusive License for Phase 3 Ready Drug to Treat Familial Adenomatous Polyposis -- Shares Jump
Biodexa Pharmaceuticals Gets Exclusive License for Phase 3 Ready Drug to Treat Familial Adenomatous Polyposis -- Shares Jump
Apr 26, 2024
10:56 AM EDT, 04/26/2024 (MT Newswires) -- Biodexa Pharmaceuticals ( BDRX ) said Friday it has signed a deal with Emtora Biosciences for the exclusive, global rights for eRapa, a phase 3-ready drug to treat familial adenomatous polyposis, an inherited condition that affects the gastrointestinal tract. Shares of the company rose more than 81% in recent Friday trading. The license...
Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe
Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe
Apr 26, 2024
11:00 AM EDT, 04/26/2024 (MT Newswires) -- Amgen ( AMGN ) said Friday it will submit a marketing authorization application to the European Medicines Agency for the teprotumumab medicine to treat moderate to severe thyroid eye disease in adults. Teprotumumab is approved for thyroid eye disease treatment in the US, Brazil and Saudi Arabia under the brand name Tepezza, the...
Update: AppFolio Swings to Q1 Adjusted Earnings, Revenue Rises; Lifts 2024 Revenue Guidance; Shares Climb
Update: AppFolio Swings to Q1 Adjusted Earnings, Revenue Rises; Lifts 2024 Revenue Guidance; Shares Climb
Apr 26, 2024
11:01 AM EDT, 04/26/2024 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph) AppFolio ( APPF ) shares were up more than 16% in recent trading on Friday, a day after the company posted stronger-than-expected Q1 earnings and raised 2024 revenue guidance. The company reported late Thursday it swung to Q1 adjusted earnings of $1.05...
Update: ResMed's Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Up Over 17%
Update: ResMed's Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Up Over 17%
Apr 26, 2024
11:01 AM EDT, 04/26/2024 (MT Newswires) -- (Updates to include recent stock movement in the headline and first paragraph.) ResMed ( RMD ) shares rose by more than 17% in recent Friday trading after the company reported fiscal Q3 non-GAAP earnings of $2.13 per diluted share, up from $1.68 a year earlier. Analysts surveyed by Capital IQ expected $1.91. Revenue...
Copyright 2023-2026 - www.financetom.com All Rights Reserved